Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Bardelli

Showing results (181-190 of 281) with videos related to

Pageof 29
Sort By:
Molecular Oncology|February 13, 2024
Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer modelsFederica Maione, Daniele Oddo, Federica Galvagno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2019
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver MutationsEzra Y Rosen, Debra A Goldman, Jaclyn F Hechtman, et al.
Cancer Discovery|May 13, 2026
Mismatch Repair-Proficient Colorectal Cancer can evade Immune Surveillance Through an Intrinsic Suppressive ProgramChiara Maria Cattaneo, Sharon Scardellato, Gianluca Mauri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2012
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomasGiorgia Migliardi, Francesco Sassi, Davide Torti, et al.
NPJ Precision Oncology|October 14, 2024
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibitionGiorgio Corti, Kristi Buzo, Enrico Berrino, et al.
The Oncologist|March 30, 2026
Degrees of H2AX phosphorylation correlate with unique features of the intratumoral immune microenvironment in colorectal carcinomasEnrico Berrino, Sara Erika Bellomo, Maria Costanza Aquilano, et al.
Nature Communications|May 1, 2015
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targetsEnzo Medico, Mariangela Russo, Gabriele Picco, et al.
Molecular Oncology|March 12, 2024
Transcriptome-wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancerElisa Mariella, Gaia Grasso, Martina Miotto, et al.
Oncotarget|August 20, 2016
Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compoundsDiego Carrella, Isabella Manni, Barbara Tumaini, et al.
Cancer Cell|December 30, 2022
Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillanceVito Amodio, Simona Lamba, Rosaria Chilà, et al.
Pageof 29

Showing results (181-190 of 281) with videos related to

Sort By:
Pageof 29
Molecular Oncology|February 13, 2024
Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer modelsFederica Maione, Daniele Oddo, Federica Galvagno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2019
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver MutationsEzra Y Rosen, Debra A Goldman, Jaclyn F Hechtman, et al.
Cancer Discovery|May 13, 2026
Mismatch Repair-Proficient Colorectal Cancer can evade Immune Surveillance Through an Intrinsic Suppressive ProgramChiara Maria Cattaneo, Sharon Scardellato, Gianluca Mauri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2012
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomasGiorgia Migliardi, Francesco Sassi, Davide Torti, et al.
NPJ Precision Oncology|October 14, 2024
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibitionGiorgio Corti, Kristi Buzo, Enrico Berrino, et al.
The Oncologist|March 30, 2026
Degrees of H2AX phosphorylation correlate with unique features of the intratumoral immune microenvironment in colorectal carcinomasEnrico Berrino, Sara Erika Bellomo, Maria Costanza Aquilano, et al.
Nature Communications|May 1, 2015
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targetsEnzo Medico, Mariangela Russo, Gabriele Picco, et al.
Molecular Oncology|March 12, 2024
Transcriptome-wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancerElisa Mariella, Gaia Grasso, Martina Miotto, et al.
Oncotarget|August 20, 2016
Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compoundsDiego Carrella, Isabella Manni, Barbara Tumaini, et al.
Cancer Cell|December 30, 2022
Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillanceVito Amodio, Simona Lamba, Rosaria Chilà, et al.
Pageof 29